Parkinson’s disease Therapeutics Market Size Share Growth Opportunities and Forecast 2022

Parkinson’s disease Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Parkinson&rsquo;s disease Therapeutics Market is segmented&nbsp;By Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT) Inhibitors, Others (includes Anticholinergic Drugs, Antihistaminics)),&nbsp;By Route of Administration (Oral, Transdermal, Subcutaneous, Others (Intestinal Infusion)),&nbsp;By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online sales),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global &quot;Parkinson&rsquo;s disease Therapeutics Market&quot;&nbsp;is expected to grow at a high <a href="https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market">CAGR of 12.4%</a> during the forecasting period (2022-2029).
</blockquote>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics:</h3>

<a href="https://www.datamintelligence.com/research-report/patient-derived-xenograft-models-market">Patient Derived Xenograft (PDX) Models Market</a>

<a href="https://www.datamintelligence.com/research-report/minoxidil-market">Minoxidil Market</a>

<a href="https://www.datamintelligence.com/research-report/krabbe-disease-treatment-market">Krabbe Disease Treatment Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

LIST OF TABLES

TABLE 01.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, 2021, 2025 &amp; 2029 , BY DRUG CLASS, ($MILLION)

TABLE 02.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029, BY DISTRIBUTION CHANNEL, ($MILLION)

TABLE 03.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029, BY ROUTE OF ADMINISTRATION, ($MILLION)

TABLE 04.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE 2021, 2025 &amp; 2029 , BY REGION, ($MILLION)

TABLE 05.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY DRUG CLASS ($MILLION)

TABLE 06.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 07.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY DISTRIBUTION CHANNEL ($MILLION)

TABLE 08.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY APPLICATION, 2018&ndash;2029 ($MILLION)

TABLE 09.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY ROUTE OF ADMINISTRATION ($MILLION)

TABLE 10.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 11.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY REGION ($MILLION)

TABLE 12.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY REGION, 2018&ndash;2029 ($MILLION)

TABLE 13.&nbsp; &nbsp; NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 14.&nbsp; &nbsp; NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 15.&nbsp; &nbsp; NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 16.&nbsp; &nbsp; NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 17.&nbsp; &nbsp; SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 18.&nbsp; &nbsp; SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 19.&nbsp; &nbsp; SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 20.&nbsp; &nbsp; SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 21.&nbsp; &nbsp; EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 22.&nbsp; &nbsp; EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 23.&nbsp; &nbsp; EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 24.&nbsp; &nbsp; EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 25.&nbsp; &nbsp; ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 26.&nbsp; &nbsp; ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 27.&nbsp; &nbsp; ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 28.&nbsp; &nbsp; ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 29.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DRUG CLASS, 2018&ndash;2029 ($MILLION)

TABLE 30.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 31.&nbsp; &nbsp; MIDDLE EAST &amp; AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

TABLE 32.&nbsp; &nbsp; GLAXOSMITHKLINE PLC: OVERVIEW

TABLE 33.&nbsp; &nbsp; GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 34.&nbsp; &nbsp; GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS

TABLE 35.&nbsp; &nbsp; SALIX PHARMACEUTICALS: OVERVIEW

TABLE 36.&nbsp; &nbsp; SALIX PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 37.&nbsp; &nbsp; SALIX PHARMACEUTICALS: KEY DEVELOPMENTS

TABLE 38.&nbsp; &nbsp; TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW

TABLE 39.&nbsp; &nbsp; TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO

TABLE 40.&nbsp; &nbsp; TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS

TABLE 41.&nbsp; &nbsp; NOVARTIS AG: OVERVIEW

TABLE 42.&nbsp; &nbsp; NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 43.&nbsp; &nbsp; NOVARTIS AG: KEY DEVELOPMENTS

TABLE 44.&nbsp; &nbsp; ORION CORPORATION: OVERVIEW

TABLE 45.&nbsp; &nbsp; ORION CORPORATION: PRODUCT PORTFOLIO

TABLE 46.&nbsp; &nbsp; ORION CORPORATION: KEY DEVELOPMENTS

TABLE 47.&nbsp; &nbsp; MYLAN N.V.: OVERVIEW

TABLE 48.&nbsp; &nbsp; MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 49.&nbsp; &nbsp; MYLAN N.V.: KEY DEVELOPMENTS

TABLE 50.&nbsp; &nbsp; STADA ARZNEIMITTEL AG.: OVERVIEW

TABLE 51.&nbsp; &nbsp; STADA ARZNEIMITTEL AG.: PRODUCT PORTFOLIO

TABLE 52.&nbsp; &nbsp; STADA ARZNEIMITTEL AG.: KG: KEY DEVELOPMENTS

TABLE 53.&nbsp; &nbsp; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.: OVERVIEW

TABLE 54.&nbsp; &nbsp; VALEANT PHARMACEUTICALS INTERNATIONAL, INC: PRODUCT PORTFOLIO

TABLE 55.&nbsp; &nbsp; VALEANT PHARMACEUTICALS INTERNATIONAL, INC: KEY DEVELOPMENTS

TABLE 56.&nbsp; &nbsp; MERCK &amp; CO., INC: OVERVIEW

TABLE 57.&nbsp; &nbsp; MERCK &amp; CO., INC: PRODUCT PORTFOLIO

TABLE 58.&nbsp; &nbsp; MERCK &amp; CO., INC: KEY DEVELOPMENTS

TABLE 59.&nbsp; &nbsp; IMPAX LABORATORIES INC: OVERVIEW

TABLE 60.&nbsp; &nbsp; IMPAX LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 61.&nbsp; &nbsp; IMPAX LABORATORIES INC: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY DRUG CLASS

FIGURE 02.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY DISTRIBUTION CHANNEL

FIGURE 03.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY ROUTE OF ADMINISTRATION

FIGURE 04.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE, 2018 &amp; 2029 (%), BY REGION

FIGURE 05.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, 2018 - 2029 AND YEAR ON YEAR GROWTH

FIGURE 06.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY DRUG CLASS&nbsp;

FIGURE 07&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY LEVODOPA COMBINATION, 2018&ndash;2029 ($MILLION)

FIGURE 08&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY DOPAMINE AGONISTS, 2018&ndash;2029 ($MILLION)

FIGURE 09&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY MONOAMINE OXIDASE B (MAO-B) INHIBITORS, 2018&ndash;2029 ($MILLION)

FIGURE 10&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ANTICHOLINERGIC DRUGS, 2018&ndash;2029 ($MILLION)

FIGURE 11&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY ANTIHISTAMINICS DRUGS, 2018&ndash;2029 ($MILLION)

FIGURE 12&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITORS, 2018&ndash;2029 ($MILLION)

FIGURE 13&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE, BY OTHERS, 2018&ndash;2029 ($MILLION)

FIGURE 14.&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY DISTRIBUTION CHANNEL

FIGURE 15&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY HOSPITAL PHARMACIES, 2018&ndash;2029 ($MILLION)

FIGURE 16&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY RETAIL PHARMACIES , 2018&ndash;2029 ($MILLION)

FIGURE 17&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY ONLINE SALES, 2018&ndash;2029 ($MILLION)

FIGURE 18&nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY ROUTE OF ADMINISTRATION

FIGURE 19&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY ORAL, 2018&ndash;2029 ($MILLION)

FIGURE 20&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY TRANSDERMAL, 2018&ndash;2029 ($MILLION)

FIGURE 21&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY SUBCUTANEOUS, 2018&ndash;2029 ($MILLION)

FIGURE 22&nbsp; &nbsp; &nbsp;GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , BY INTESTINAL INFUSION, 2018&ndash;2029 ($MILLION)

FIGURE 23&nbsp; &nbsp; GLOBAL PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY REGION

FIGURE 24&nbsp; &nbsp; &nbsp;NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 25&nbsp; &nbsp; &nbsp;NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY PRODUCT DRUG CLASS, 2018&ndash;2029 ($MILLION)

FIGURE 26&nbsp; &nbsp; &nbsp;NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 27&nbsp; &nbsp; &nbsp;NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

FIGURE 28&nbsp; &nbsp; &nbsp;NORTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)&nbsp;

FIGURE 29&nbsp; &nbsp; SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 30&nbsp; &nbsp; &nbsp;SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY PRODUCT DRUG CLASS, 2018&ndash;2029 ($MILLION)

FIGURE 31&nbsp; &nbsp;SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 32&nbsp; &nbsp; &nbsp;SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

FIGURE 33&nbsp; &nbsp; &nbsp;SOUTH AMERICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 34&nbsp; &nbsp; &nbsp;EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 35&nbsp; &nbsp;EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY PRODUCT DRUG CLASS, 2018&ndash;2029 ($MILLION)

FIGURE 36&nbsp; &nbsp; &nbsp;EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 37&nbsp; &nbsp;EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

FIGURE 38&nbsp; &nbsp; EUROPE PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 39&nbsp; &nbsp; &nbsp;ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 40&nbsp; &nbsp; &nbsp;ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY PRODUCT DRUG CLASS, 2018&ndash;2029 ($MILLION)

FIGURE 41&nbsp; &nbsp; ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 42&nbsp; &nbsp; &nbsp;ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

FIGURE 43&nbsp; &nbsp; &nbsp;ASIA PACIFIC PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 44&nbsp; &nbsp; MIDDLE EAST AND AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 45&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY PRODUCT DRUG CLASS, 2018&ndash;2029 ($MILLION)

FIGURE 46&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 47&nbsp; &nbsp; &nbsp;MIDDLE EAST AND AFRICA PARKINSON&rsquo;S DISEASE THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2018&ndash;2029 ($MILLION)

FIGURE 48.&nbsp; &nbsp; GLAXOSMITHKLINE PLC: FINANCIALS

FIGURE 49.&nbsp; &nbsp; SALIX PHARMACEUTICALS: FINANCIALS

FIGURE 50.&nbsp; &nbsp; TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIALS

FIGURE 51.&nbsp; &nbsp; NOVARTIS AG.: FINANCIALS

FIGURE 52.&nbsp; &nbsp; ORION CORPORATION: FINANCIALS

FIGURE 53.&nbsp; &nbsp; MYLAN N.V.: FINANCIALS

FIGURE 54.&nbsp; &nbsp; &nbsp;STADA ARZNEIMITTEL AG.: FINANCIALS

FIGURE 55.&nbsp; &nbsp; VALEANT PHARMACEUTICALS INTERNATIONAL, INC: FINANCIALS

FIGURE 56&nbsp; &nbsp;MERCK &amp; CO., INC: FINANCIALS

FIGURE 57.&nbsp; &nbsp; IMPAX LABORATORIES INC: FINANCIALS

&nbsp;